RNAi inhibition of alpha-ENaC expression
First Claim
Patent Images
1. A composition comprising an iRNA agent comprising a first strand and a second strand, wherein:
- a. the sequence of the first strand is the sequence of (SEQ ID NO;
223, and the sequence of the second strand is the sequence of SEQ ID NO;
224;
orb. the sequence of the first strand is the sequence of SEQ ID NO;
527, and the sequence of the second strand is the sequence of SEQ ID NO;
528;
orc. the sequence of the first strand is the sequence of SEQ ID NO;
1281, and the sequence of the second strand is the sequence of SEQ ID NO;
1282.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
37 Citations
20 Claims
-
1. A composition comprising an iRNA agent comprising a first strand and a second strand, wherein:
-
a. the sequence of the first strand is the sequence of (SEQ ID NO;
223, and the sequence of the second strand is the sequence of SEQ ID NO;
224;
orb. the sequence of the first strand is the sequence of SEQ ID NO;
527, and the sequence of the second strand is the sequence of SEQ ID NO;
528;
orc. the sequence of the first strand is the sequence of SEQ ID NO;
1281, and the sequence of the second strand is the sequence of SEQ ID NO;
1282. - View Dependent Claims (2, 3, 4, 5, 9)
-
-
6. A composition comprising an iRNA agent comprising a first strand and a second strand, wherein the sequences of the first strand and the second strand are the sequences of SEQ ID NOs:
- 223 and 224, respectively.
- View Dependent Claims (15, 16)
-
7. A composition comprising an iRNA agent comprising a first strand and a second strand, wherein the sequences of the first strand and second strand are the sequences of SEQ ID NOs:
- 527 and 528, respectively.
- View Dependent Claims (17, 18)
-
8. A composition comprising an iRNA agent comprising a first strand and a second strand, wherein the sequences of the first strand and second strand are the sequences of SEQ ID NOs:
- 1281 and 1282, respectively.
- View Dependent Claims (19, 20)
-
10. A composition comprising an iRNA agent to alpha-ENaC, wherein the iRNA agent comprises a first strand and a second strand,
wherein the sequence of the first strand is the sequence of SEQ ID NO: - 223, SEQ ID NO;
527, or SEQ ID NO;
1281, andwherein the sequence of the second strand is the sequence of SEQ ID NO;
224, SEQ ID NO;
528, or SEQ ID NO;
1282,the composition further comprising an epithelial receptor ligand. - View Dependent Claims (11)
- 223, SEQ ID NO;
-
12. A method of treating a human subject having a pathological state mediated at least in part by alpha-ENaC expression, the method comprising the step of administering to the subject a therapeutically effective amount of a composition comprising an iRNA agent comprising a first strand and a second strand, wherein:
-
a. the sequence of the first strand is the sequence of SEQ ID NO;
223, and the sequence of the second strand is the sequence of SEQ ID NO;
224;
orb. the sequence of the first strand is the sequence of SEQ ID NO;
527, and the sequence of the second strand is the sequence of SEQ ID NO;
528;
orc. the sequence of the first strand is the sequence of SEQ ID NO;
1281, and the sequence of the second strand is the sequence of SEQ ID NO;
1282. - View Dependent Claims (13, 14)
-
Specification